Condition: Small Cell Lung Carcinoma · Large Cell Neuroendocrine Carcinoma of the Lung · Neuroendocrine Prostate Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University Of Iowa | Iowa City, Iowa, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Corewell Health William Beaum Hosp | Royal Oak, Michigan, United States | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Seoul, Seoul, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07006727